CHNC China Infrastructure Construct

CHNC Completes Review of Its First Three Fiscal Quarters

CHNC Completes Review of Its First Three Fiscal Quarters

HOUSTON, TX, July 12, 2022 (GLOBE NEWSWIRE) -- via – China Infrastructure Construction Corp., a company traded on the OTC Markets Pink tier under the symbol CHNC, announces that, in addition to completing its public audit successfully on March 21, 2022, its independent registered public accounting firm, PWR CPA LLP, has completed its review of the Company’s financial statements for the first three quarters of the fiscal year that ended May 31, 2022. This review is a significant step in the prompt completion of audited financial statements for the fiscal year then ended, as well as in preparing for the change of the Company’s corporate name to Cannabis Bioscience International Holdings, Inc., which it plans to accomplish as soon as it is able to comply with regulatory requirements.

The new name will enable the Company to identify itself with the business that it conducts, including cannabis-related education, research, clinical studies and science applied for the benefit of people's health.

CHNC is preparing to move ahead by providing greater transparency and credibility to the public as a result of its having audited financial statements. The Company believes that doing so will enable it to expand its alliances, have better access to financing and take advantage of business opportunities. The Company is considering taking the steps that would enable it to become an OTCQB company. "From the beginning, we have set higher standards that require us to be the best version of ourselves, making us stand out from other OTC companies," says Henry Levinski, CHNC’s VP/Treasurer.

We will continue to send updates on our progress and appreciate the confidence of our investors. We celebrate knowing that we have overcome every hurdle our company has faced to date.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases.

Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

For more information contact us at:



817/528-2475 for English

214/733-0868 for Spanish

Or visit





EN
12/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on China Infrastructure Construct

 PRESS RELEASE

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassific...

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassification HOUSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CBIH is proud to announce that Brian Cuban, Esq., a distinguished attorney, best-selling author, mental health advocate, and esteemed member of our Advisory Board, has officially joined the Reclassification Team. Mr. Cuban will play a crucial role in representing CBIH at the upcoming DEA hearings on marijuana rescheduling. Brian Cuban, the younger brother of entrepreneur Mark Cuban, brings a unique combination of personal recovery experience and professional advocacy to ...

 PRESS RELEASE

Cannabis Bioscience International Holdings (CBIH) Announces Partnershi...

Cannabis Bioscience International Holdings (CBIH) Announces Partnership with Stephen Gould for Manufacturing and Distribution of Medical Products HOUSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is thrilled to announce a groundbreaking partnership with Stephen Gould, marking a monumental step forward in the manufacturing and distribution of CBIH’s advanced medical product line. This collaboration represents a shared commitment to excellence and innovation in the healthcare industry. Stephen Gould, a company with a remarkable presence...

 PRESS RELEASE

CBIH Files Petition to Include Alexis Bortell as Witness in DEA Resche...

CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing HOUSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (CBIH) continues its unwavering advocacy for cannabis as a legitimate medicine by formally petitioning to have Ms. Alexis Bortell, long-time cannabis advocate and patient, to serve as a witness in the upcoming DEA hearing on marijuana rescheduling. Alexis Bortell has been a leading voice in the fight for medical cannabis access since being diagnosed with intractable epilepsy at the age of seven. After enduring years...

 PRESS RELEASE

A Letter from the Desk of CBIH

A Letter from the Desk of CBIH HOUSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings CEO Dante Picazo Addresses Cannabis Reclassification and DEA Hearings Dear Community, On Monday, December 2, I had the honor of representing Cannabis Bioscience International Holdings (CBIH) at the DEA Hearing Docket No. 1362 and Hearing Docket No. 24-44, focused on the reclassification of cannabis. Being chosen to speak on behalf of not only our company but also medicine, science, and patients is a privilege and a profound responsibility. CBIH remains committed to activ...

 PRESS RELEASE

CBIH Advocates for Cannabis Policy Reform at DEA Reclassification Hear...

CBIH Advocates for Cannabis Policy Reform at DEA Reclassification Hearing HOUSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) proudly announces its active participation in today’s DEA meaningful hearing on cannabis reclassification. Representing CBIH at this critical event in Arlington, Virginia, is Dante Picazo, the company’s esteemed Director and CEO, bringing years of expertise and leadership in the medical cannabis industry to Docket No. 1362, Hearing Docket No. 24-44. Mr. Picazo has presented a comprehensive 78-page statement that un...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch